Influence of Human Platelet Derivatives on Dental Implant

Sponsor
Al-Mustansiriyah University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06044246
Collaborator
(none)
30
1
2
9
3.3

Study Details

Study Description

Brief Summary

The goal of this randomized controlled trial is to evaluate the benefit of PRF membrane on bone around dental implant in patients who need treatment with dental implant.

Aims of the study:
  • To study the effect of PRF membrane (with or without bone substitute on increasing bone dimension around dental implant.

  • To investigate the effects of compositions of PRF (platelets count, WBC count) on bone healing.

Condition or Disease Intervention/Treatment Phase
  • Biological: PRF membrane
N/A

Detailed Description

Materials and methods:

PRF will be obtained from a blood sample that is taken from the patient at the time of surgery in 10-mL tubes, the blood-containing tube is placed in a centrifuge at specially controlled rotations, temperature and time. The result is the separation of blood, basically from two by-products, including PRF. The PRF clot will be placed in specific box ( P.R.F -System; Surgident, CE ) to create a PRF membrane with specific thickness that will be placed on the bone around dental implant.

Evaluation of the results

  • Alveolar bone width around dental implant will be measured.

  • Histological examination of the tissue that excised during dental implant uncover surgery.

  • Evaluate pain by visual analogue score (VAS).

  • Estimate the count of WBC and platelets in whole blood will be obtained from a laboratory results.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Influence of Human Platelet Derivatives on Dental Implant Osseointegration
Anticipated Study Start Date :
Oct 1, 2023
Anticipated Primary Completion Date :
May 1, 2024
Anticipated Study Completion Date :
Jul 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: experimental group

Placing dental implant with PRF membrane treatment alone or combined with bone substitute.

Biological: PRF membrane
Placing implant with PRF membrane treatment

No Intervention: control group

Placing dental implant

Outcome Measures

Primary Outcome Measures

  1. Osseointegration [Immediately after surgery, after 12 weeks (during uncover implant surgery)]

    Evaluation of the changes in the degree of osseointegration will be performed using Osstell devise. [Osstell ISQ device. (Stampgatan, Gteborg, Sweden)] The Unit of measurement: ISQ (Implant Stability Quotient), which is a scale from 1 to 100.

  2. Bone width [Baseline (pre-surgery), immediately after the surgery, after 4 weeks, 6 weeks, 8weeks, 10 weeks, and 12 weeks.]

    Measure the dimensional changes using special caliper (vernier) measurement tool, to evaluate the changes of bone width around dental implant. the Unit of measurement: millimeter (mm) (Bone and mucosa)

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes

IInclusion criteria

  • Non- smoker.

  • No medical history of any systemic diseases that affect the bone metabolism.

  • Did not receive any systemic drugs.

  • Has edentulous area that needs dental implant.

The exclusion criteria were as follows:
  • Systemic disease or medication compromising bone and soft tissue healing.

  • Pathology in the edentulous region.

  • Bruxism.

  • Disease of the oral mucosa.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Kadhimiya Teaching HospitalKadhimiya Educational Hospital Baghdad Alkadhmiya City Iraq 60 St

Sponsors and Collaborators

  • Al-Mustansiriyah University

Investigators

  • Principal Investigator: Assis. Prof. Dr. Afya SD Al-radha, College of Dentistry, Mustansiriyah University.

Study Documents (Full-Text)

More Information

Publications

None provided.
Responsible Party:
Afya Sahib Diab Al-radha, Assistant Professor, Al-Mustansiriyah University
ClinicalTrials.gov Identifier:
NCT06044246
Other Study ID Numbers:
  • MUOSU-202103
First Posted:
Sep 21, 2023
Last Update Posted:
Sep 21, 2023
Last Verified:
Sep 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Afya Sahib Diab Al-radha, Assistant Professor, Al-Mustansiriyah University

Study Results

No Results Posted as of Sep 21, 2023